Appili Therapeutics Inc.
APLIF
$0.01
$0.000.00%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -60.38% | -88.23% | -88.23% | -89.47% | -27.06% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -60.38% | -88.23% | -88.23% | -89.47% | -27.06% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -60.38% | -88.23% | -88.23% | -89.47% | -27.06% |
| SG&A Expenses | -10.72% | -12.29% | -15.11% | -24.13% | -34.74% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -27.68% | -7.24% | 11.35% | 10.41% | 13.19% |
| Operating Income | 26.03% | -0.57% | -21.55% | -24.98% | -16.43% |
| Income Before Tax | 32.22% | 41.29% | 30.92% | 25.92% | 54.06% |
| Income Tax Expenses | 399.17% | -16.51% | -74.66% | -99.20% | -83.05% |
| Earnings from Continuing Operations | 30.26% | 40.93% | 31.74% | 26.85% | 54.41% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 30.26% | 40.93% | 31.74% | 26.85% | 54.41% |
| EBIT | 26.03% | -0.57% | -21.55% | -24.98% | -16.43% |
| EBITDA | 26.07% | -0.57% | -21.60% | -25.00% | -16.41% |
| EPS Basic | 30.41% | 40.95% | 31.17% | 26.69% | 54.41% |
| Normalized Basic EPS | 32.35% | 41.67% | 30.77% | 23.86% | 52.94% |
| EPS Diluted | 30.41% | 40.95% | 31.17% | 26.69% | 54.41% |
| Normalized Diluted EPS | 32.35% | 41.67% | 30.77% | 23.86% | 52.94% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.03% | 0.03% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.03% | 0.03% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |